Discover how new global guidelines aim to combat the rising threat of Candida infections with updated treatments and ...

The new guidelines provide updated diagnostic and therapeutic strategies for both mucocutaneous and invasive candidiasis.

Medically reviewed by Edmund Khoo, DDS Thrush, or oral candidiasis, is a fungal infection in your mouth and throat. It is ...

SCYNEXIS (NASDAQ:SCYX – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Thursday. SCYNEXIS Stock Up 8.6 % ...

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted ...

In a study set to be published in Mycology, a research team led by Prof. Jianping Xu from McMaster University and researcher Jinyan Wu from Hainan Medical University presents new findings on Candida ...

Investment analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Cidara Therapeutics in a report ...

Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or "ZCT"), a FemTech medical device company revolutionizing ...

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

In the complex ecosystem of the human body, yeast exists as a quiet inhabitant, typically harmless but capable of causing ...

Also, no serious adverse events nor events of oral or gastrointestinal candidiasis, commonly seen in EOE patients being treated with steroids, have been observed in any of the first six Cohorts." ...